BioSpace News Archive

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close.

As per 30 June 2023 , the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares.

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call.

Benzodiazepine use and discontinuation is associated with nervous system injury and negative life effects that continue after discontinuation, according to an article published 06/29/2023 in the open access journal PLOS ONE , noted the Alliance for Benzodiazepine Best Practices.

FSD Pharma Inc. announced today the results of its annual general and special meeting of shareholders (“ AGSM ”), held online and in virtual-only format on June 29, 2023.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com.

SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII) today announces the first successful surgical procedure at the National Institute of Tuberculosis and Respiratory Diseases (NITRD) in New Delhi, India using the SSi Mantra surgical robotic system.

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis.

SciSparc Ltd. today announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its Phase IIb clinical trial to use SCI-110 for treating adults with Tourette Syndrome (“TS”) at the Hannover Medical School in Hannover, Germany.

Pasithea Therapeutics Corp. confirms its Board of Directors has previously formed a special committee of independent and disinterested directors to assess an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.